reason report
anoth stellar rais reinforc view cgm
bottom line today market close report strong
beat sale y/i ahead consensu
ahead us ytd price headwind basic
line manag expect out-performance seem
pure volume-baseda encourag sustain near
long-term trend importantli manag rais
sale guidanc raisenow
midpoint bring total
ytd guidanc rais despit sale beat
us highlight manag confid go-forward
outlook share trade market could
attribut sale growth deceler even above-
beat guidanc rais deceler comp-adjust basi
much less meaning point vs point think
like newly-rais guidanc could still prove conserv
larg time sale vs deceler growth end user
demand ultim think strong perform quarter
push share higher wed view possibl weak
buy opportun given clearli seem continu
adopt inflect signific runway ahead continu
hold major share posit best-in-class reput
doesnt seem wane despit ramp competit type
 still penetr likelyw believeto ramp
close within next five year insulin-depend type
penetr also signific likelihood ramp
least major patient runway long believ
retain market-lead posit
reiter op rate pt pt appli ev/sal
sale share current trade
sale premium compar smid-cap med-tech
compani nxtm
believ continu deliv estim upsid sustain
ev/sal multipl current level ultim believ share
warrant least modest premium small-cap med-tech stock
univers given massiv highli under-penetrated total
address market per estim consist upsid
potenti top-tier growth outlook longer term
outlook higher sale
estim move higher y/i y/
vs previous alreadi reflect
point price headwind
medic suppli devic
sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate inc share outperform price target
longer term view continu glucos monitor cgm market opportun
compel potenti top estim target larg grow under-tr
patient popul type diabet initi ultim move much-larg type
patient popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancreasessenti
cgm-augment insulin pump system automat accur dose patient
launchingi like sustain sale growth near medium term despit
type product conjunct googl partnership help drive project sale
compound-annual-growth-rate period
next month believ share could trade appli ev/
sale sale share current trade
sale premium compar smid-cap med-tech compani
nxtm believ continu deliv estim upsid
sustain ev/sal multipl current level ultim believ share warrant
least modest premium small-cap med-tech stock univers given
massiv highli under-penetrated total address market per estim
consist upsid potenti top-tier growth outlook longer term
risk includ failur continu evolv sensor technolog includ verili product
type patient toward sensor-integr pump potenti price pressur
increas competit potenti product recal reimburs issu
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
total good sold
research develop
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
total good sold
research develop expens
sg sale
 sale
oper expens sale
compani report svb leerink estim
partner novo nordisk
partnership verili formerli googl life scienc
develop bandage-lik sensor togeth data analyt
address non-insulin-us type market sensor
label day
miniatur dispos bandage-lik sensor size
trial complet
feb acceler effort verili expect complet
develop
time depend calibr
feb initi feasibl studi complet
studi compar glycem qualiti life benefit
monitor cgm self-monitor blood glucos smbg
made studi particip primari care physician
decis base insight real-tim use
retrospect insight determin remot visit
studi assess patient type diabet
sub-optimal glycem control use multipl oral agent
abl make lifestyl chang result improv
glycem control use real-tim continu glucos
monitor rt-cgm target learn modul versu
 juli timelin affirm late earli launch
plan enrol patient
prospect random multicent two-arm confirmatori studi plan enrol
non-gaap oper margin
ebitda margin
oper margin ebitda margin
oper margin ebitda
margin
increas includ increment
spend on-intens
spend on-intens program
spend on-intens program
spend on-intens program
low-end
end
end
end
